G Proteins couple receptors for diverse extracellular
signals to effecters such as enzymes and ion channels.
The majority of polypeptide hormones, all monoamine neurotransmitters, PGs, and even extracellular Ca'+ signal their target cells through G protein-coupled receptors (GPCR). In the past few years, mutations in G proteins and GPCR have been identified as the causes of several endocrine diseases. Understanding the molecular basis of these diseases provides valuable insights into G protein and GPCR structure and function, and may be important for diagnosis and treatment. In this paper, I briefly describe G protein-coupled signal transduction, provide a general framework for understanding how G protein and GPCR mutations cause endocrine disease, review specific endocrine disorders caused by G protein and GPCR mutations, and speculate on implications of this work for the etiology, diagnosis, and treatment of endocrine disorders.
G Protein-coupled signal transduction: a brief overview of structure and function For detailed coverage of the enormous body of data on the structure and function of G proteins and GPCR, the interested reader is referred to several recent monographs (1, 2) and reviews (3, 4) . Due to limitations of space, here I will give only a brief overview, emphasizing some features relevant to the pathophysiology of endocrine disorders caused by defective G protein-coupled signal transduction. GPCR comprise a superfamily sharing a common structural and functional motif (1, 3, 5) , a single polypeptide with seven membrane-spanning domains.
All GPCR act by promoting the release of tightly bound GDP from G protein a-subunits, thereby enabling GTP to bind and activate the G protein ( Fig. 1) . Within the GPCR superfamily, differences in sequence and structure presumably contribute to differences in ligand recognition and G protein coupling. For small ligands such as catecholamines, the binding site is within the membrane bilayer in a pocket formed by several of the mem- G proteins consist of three distinct polypeptide gene products (2, 4). The a-subunit binds guanine nucleotides with high affinity and specificity. The P-and y-polypeptides are tightly, but noncovalently, associated in a functional dimer subunit. The heterotrimer, associated with the inner surface of the plasma membrane ( Fig. l) , is required for high affinity coupling to GPCR. Upon a-subunit binding of GTP and dissociation from the /3y-dimer, each subunit can independently modulate the activity of one or more effecters, such as adenylyl cyclase (the enzyme that generates the second messenger CAMP), other second messenger-generating enzymes, and ion channels. There are 16 mammalian a-subunit genes. They vary in range of expression and specificity of receptor-effector coupling. Some, such as G5~, which is responsible for stimulation of CAMP formation, are expressed ubiquitously.
Based on the degree of amino acid identity, they have been divided into 4 subfamilies: G,, G,, G,, and G,,. Members of the G, and G, subfamilies, in general, mediate stimulatory events such as hormone secretion, whereas members of the Gi subfamily generally mediate inhibition of processes such as hormone secretion. The physiological roles of members of the G,, subfamily and, indeed, the receptors and effecters they couple have not yet been clearly defined. In each panel, the stippled region denotes the plasma membrane, with the extracellular area above and the intracellular area belozu. In the basal state, the G protein is a heterotrimer with GDP tightly bound to the cr-subunit. The agonistactivated receptor catalyzes the release of tightly bound GDP that permits GTP to bind. The GTP-bound o-subunit dissociates from the p-y-dimer. Arrows between GTP-bound o-subunit and effector and between fly-dimer and effector indicate the regulation of effector activity by the respective subunits. Under physiological conditions, effector regulation by G protein subunits is transient and is terminated by the GTPase activity of the u-subunit. The latter converts bound GTP to GDP, thus returning the o-subunit to its inactivated state with high affinity for the py-dimer, which reassociates to again form the heterotrimer.
and G proteins, including changes in the level of expression or in posttranslational modifications. A number of studies describe alterations in signal transduction in conditions such as hypertension and aging. Altered signal transduction has been ascribed to quantitative changes in G protein expression or qualitative changes in receptor-G protein coupling (7, 8) . Generally, however, the observed changes in signal transduction are modest, and the molecular basis for such changes has not been clearly defined. The pathophysiological significance of such subtle differences in G protein (or GPCR) expression and function remains to be proven.
In contrast, mutations in G proteins and GPCR have been identified that unequivocally alter signal transduction with clear-cut, and sometimes devastating, pathophysiological consequences. There are three principal determinants of the phenotypic expression of such mutations: 1) the range of expression of the mutated gene; mutations in a ubiquitously expressed gene such as Gs~, in general, will cause more generalized manifestations than those caused by mutations in a gene such as the LH receptor, which is more restricted in expression (but see the following); 21 germ-line (inherited) VS. somatic (postzygotic) mutations; the former potentially cause manifestations in every cell in which the gene is expressed; somatic mutation of even a ubiquitously expressed gene, in contrast, would still lead to manifestations that are localized to the cells derived from the progenitor in which the original somatic mutation occurred; and 3) the nature of the mutation; mutations can be broadly divided into those causing gain and those causing loss of function.
Loss of function mutations block normal messenger ribonucleic acid and/or protein synthesis, prevent the synthesized protein from reaching its normal subcellular location (the plasma membrane in the case of GPCR and G proteins; see no. 1 in Fig. l) , or impair function despite synthesis and normal targeting of the protein. Many GPCR mutations, including missense mutations, will cause abnormal folding of the protein with retention in the endoplasmic reticulum. Such trafficking mutations of rhodopsin, the GPCR mediating visual transduction, have been well described as a cause of retinitis pigmentosa (9), but undoubtedly also occur in G protein-coupled hormone receptors. GPCR mutations compatible with normal protein synthesis and trafficking may, nonetheless, cause loss of function by impairing agonist binding to or activation of receptor (no. 2 in Fig. 1 ) or by impairing receptor coupling to activation of G protein (no. 3 in Fig. 1 ). G protein loss of function mutations, in addition to impairing normal protein synthesis or trafficking, may block receptor coupling or activation by GTP (no. 3 in Fig. 1 ) or impair effector interaction (no. 4 in Fig. 1 ).
Gain of function mutations cause inappropriate or constitutive activation. A constitutively activated GPCR signals G protein activation, even without the hormone binding that normally activates the receptor. Likewise, a constitutively activated G protein signals its effector despite the lack of normal upstream signals from a hormone-activated GPCR. Such mutations could either accelerate the release of GDP and lead to receptor-independent G protein activation (no. 3 in Fig. 1 ) or block the guanosine triphosphatase (GTPase) reaction that terminates G protein activation (no. 5 in Fig. 1 ). Gain of function mutations are by definition dominant, and thus, heterozygotes for germ-line mutations will be clinically affected. For loss of function mutations, the situation is more complex. Pure loss of function mutations may cause no overt clinical dysfunction in heterozygotes. For many GPCR, there is sufficient signal sensitivity and amplification such that a 50% reduction in receptor number does not lead to clinically apparent disease. Certain loss of function mutations may act as dominant negatives and thereby also cause clinical disease in heterozygotes. In theory, a mutant GPCR that binds to its cognate G protein but fails to activate it or a mutant G protein that binds receptor or effector without resultant activation could act as dominant negatives, but definite examples of such mutations of either GPCR or G proteins as a cause of disease have yet to be identified.
Loss of function mutations are generally associated with inherited disorders, whereas gain of function mutations may occur in the germ line in inherited disorders or as somatic events in sporadic disorders. In the latter case, a gain of function mutation confers a proliferative advantage on the cell in which the somatic event occurs, leading to a clonal neoplasm and eventually clinically evident disease. Germline mutations of certain GPCR and G proteins may never be detected simply because they would be incompatible with life. This could be true of both heterozygous gain of function mutations and homozygous null mutations in which inappropriate signal activation or total lack of signaling, respectively, would be lethal. When such germ-line mutations are compatible with life, the timing of onset of clinical disease may be quite variable even though the mutation is already present at birth. by increased circulating concentrations of the corresponding hormone agonist. Gain of function mutations will lead to a state resembling hypersecretion of the hormone normally activating the involved GPCR, but circulating concentrations of the involved hormone will actually be suppressed, reflecting autonomous hyperfunction of the target gland. In the following sections, specific diseases caused by GPCR and G protein mutations are described. Space does not permit a comprehensive listing of each individual mutation, but selected examples will be cited. For a detailed listing of mutations in G proteins and GPCR identified to date (note that new ones are continually being reported), the reader is referred to several recent reviews (1, 10,ll). NSPHT is caused by homozygous CaR gene mutation in some infants who are products of consanguineous marriages (29, 30). Knock-out of the CaR gene in mice causes an FHH-like syndrome in heterozygotes and is lethal in the early postnatal period in homozygotes (31). Not all cases of NSPHT are due to homozygous CaR mutation; some may be compound heterozygotes, and in some, other factors may be involved. Two cases of NSPHT due to de nova heterozygous CaR mutations were reported, prompting the researchers to speculate about a dominant negative effect of the mutation, but the phenotype was milder in these cases with serum calcium elevation much less marked than in subjects with homozygous mutation of the CaR (32). A homozygous missense mutation (proline 40 to alanine) was identified in a Japanese subject with relatively benign (FHH-like) disease (33). The consanguineous parents showed only borderline serum Ca2+ elevation. Although the functional significance of the mutation was not defined by expression studies, the researchers speculated that a spectrum of mutations exists such that those causing a milder degree of loss of function may cause relatively benign disease even in the homozygous form. Given the link between CaR mutations and abnormal parathyroid function in FHH and NSPHT, it is possible that CaR dysfunction is involved in some forms of sporadic hyperparathyroidism.
A study of 44 parathyroid tumors, including adenomas, carcinomas, and hyperplasia, however, failed to reveal somatic mutations in the CaR gene (34).
Gain of function mutations
After site-directed mutagenesis of adrenergic receptors showed that missense mutation of critical residues in the third intracellular loop caused constitutive activation (351, similar, naturally occurring mutations were identified in the receptors for LH (36) and TSH (37) ( Table 1) . Activating mutations of the LH receptor cause familial male precocious puberty, an autosomal dominant disorder in which affected males show signs of virilization often by age 4 yr or even earlier. The disease may also occur sporadically (38) as either a new germ-line mutation or a somatic event. Gonadotropins are suppressed compatible with autonomous gonadal hyperfunction. Aspartate 578 (in the sixth transmembrane domain) to glycine is a common missense mutation found in familial male precocious puberty, but a number of other missense mutations have been identified (10). An aspartate 578 to tyrosine mutation was identified in a subject with onset of precocious puberty by 1 yr of age (39). This mutant causes even greater CAMP stimulation than other constitutively activated LH receptor mutants tested in transfected cells, suggesting a correlation between degree of constitutive activation and timing of disease onset. Interestingly, there are no apparent clinical manifestations in obligate female carriers of the mutant receptor gene. Evidently, LH receptor activation of CAMP formation in testicular Leydig cells is sufficient to stimulate testosterone production and even spermatogenesis, but is ineffective in triggering puberty in females without concomitant FSH action.
Constitutive activation of the TSH receptor is caused by somatic mutations identified in hyperfunctioning thyroid adenomas (toxic or "hot" nodules) (37) and by germ-line mutations in familial nonautoimmune hyperthyroidism (40, 41) . TSH is suppressed as expected with autonomous thyroid hyperfunction. In the reported pedigrees with familial hyperthyroidism, clinical onset of disease ranged from 18 months to adulthood. Aggressive ablative treatment was required to avoid relapse of this form of disease (42). In transgenic mouse models of hyperthyroidism caused by constitutive receptor activation, foci of transformed thyrocytes have been found in older animals, raising the question of whether chronic stimulation of the CAMP cascade can lead or predispose to malignant transformation (42). Identification of an alanine 623 to serine mutation of the TSH receptor in three well differentiated thyroid carcinomas suggests that this may indeed be possible (43). Whereas activating LH receptor mutations tend to cluster in the sixth transmembrane domain and adjacent intracellular loop, activating TSH receptor mutations are dispersed more widely, suggesting that the TSH receptor is intrinsically more susceptible to activation (42).
Activating GPCR mutations have also been identified as causes of inherited forms of hypo-and hypercalcemia. In the former, missense mutations of the CaR were found in an autosomal dominant form of hypoparathyroidism with mild hypocalcemia (44, 45). Expression of one such mutation, glutamate 128 to alanine, showed increased sensitivity to activation by Ca2+ (44). Presumptively, receptor activation at inappropriately low serum Ca2+ inhibits PTH secretion, causing hypoparathyroidism. Because of the expected effect of CaR activation in the kidney, one would predict inappropriately high renal calcium excretion in affected individuals.
A heterozygous activating mutation of the PTH/PTHrP receptor gene (histidine 223 to arginine in the first intracellular loop) was identified in a subject with a rare form of dwarfism, termed Jansen-type metaphyseal chondrodysplasia (46). This disease is associated with PTH-independent hypercalcemia consistent with constitutive PTH receptor activation mimicking the effect of a systemic increase in PTH. Abnormal endochondral bone formation in this disorder reflects the critical role of the PTH/PTHrP receptor in normal proliferation and differentiation of growth plate chondrocytes (47). and 2) the occurrence of the identical G,a gene mutation within a kindred in subjects with PHI' and pseudo-PHI'.
The latter lack hormone resistance altogether (note that a mutant G,a gene is never found in completely unaffected individuals within such kindreds).
It appears that a heterozygous loss of function mutation of the G,a! gene is necessary, but not sufficient, Two males have been reported with typical features of PHI' Ia, but, in addition, with gonadotropin-independent precocious puberty.
A germ-line alanine 366 to serine mutation of the G,cw gene was identified in both subjects (49). Expression of the mutant protein showed that it was rapidly degraded at 37 C (i.e. a loss of function mutation), but that at 32 C, the protein was constitutively activated due to receptor-independent GDP release (step 3 in Fig. 1 ). This suggested that the clinical features of PHP Ia are due to the G,CX loss of function mutation, whereas at the lower temperature prevailing in the testes, the mutant G,(Y is activated, rather than degraded, and causes precocious puberty by stimulating Leydig cell CAMP formation (49).
Activating heterozygous mutations of the G,cw gene have been identified in pituitary somatotroph tumors in subjects with acromegaly and in hyperfunctioning thyroid adenomas (50). These occur as somatic, rather than germ-line, events, explaining the focal disease manifestations. About 40% of tumors from subjects with acromegaly show G,a-activating mutations (51). Hyperfunctioning thyroid adenomas may be caused by either activating TSH receptor mutations (see earlier) or activating G,cu mutations. The former may predominate (42), but a recent study of 37 thyroid adenomas found only 3 TSH receptor mutations and 9 Gs~ mutations (52). The G,cu gene-activating mutations identified to date involve either arginine 201 or glutamine 227. These residues are critically involved in GDP/GTP binding, and mutation of either inhibits G protein GTPase activity, causing constitutive activation. These residues are highly conserved in all G protein a-subunits, and naturally occurring mutations involving the same amino acids have been found in the G,Z~ gene in adrenal cortical and ovarian neoplasms (50) ( Table 2) . This observation has not been confirmed in other studies (53), nor is the etiological significance of these Gi+ mutations clear. In contrast, activating G,(Y mutations offer a plausible explanation for somatotroph and thyroid tumors because stimulation of the CAMP cascade by GHRH and TSH is known to promote cell proliferation and increased hormone secretion of the somatotroph and thyrocyte, respectively (54). The McCune-Albright syndrome (MAS) is characterized by polyostotic fibrous dysplasia, cafe-au-lait skin hyperpigmentation, and autonomous endocrine hyperfunction (classically gonadotropin-independent precocious puberty, but acromegaly, hyperthyroidism, and adrenal cortical hyperfunction have also been described).
The disorder is sporadic rather than inherited.
Activating mutations of arginine 201 of the G,a gene have been found in a mosaic distribution in tissues of subjects with MAS (55). This is consistent with the idea that a somatic mutation of G,a occurs as an early postzygotic event. According to this hypothesis, a germ-line activating mutation of G,a would be lethal, but an early somatic mutation, although nonlethal, would cause widespread disease manifestations reflecting the mwaic distribution of the mutation. The increased CAMP formation caused by the mutation offers an explanation not only for the endocrine hyperfunction (see above), but also for the skin hyperpigmentation that is normally mediated by MSH acting through a G,a-coupled receptor to increase CAMP. Activating G,a mutations have also been identified in affected bone from subjects with fibrous dysplasia (both polyostotic and monostotic), but the pathophysiology of this lesion requires further study (56). It appears that the time of occurrence of somatic G,cw mutations determines the nature and distribution of the manifestations. Mutations occurring very early in embryogenesis may cause pleiotropic, potentially lethal manifestations (57), whereas those occurring much later cause focal diseases, such as somatotroph tumors or monostotic fibrous dysplasia.
Speculations Concerning Future Developments Discovery of other defects in G protein-coupled signal transduction in endocrine disorders
It is likely that additional endocrine (and nonendocrine) human diseases will be found to be caused by mutations in GPCR and G protein a-subunits. Many GPCR and several G proteins are involved in cell growth regulation. In transfection assays, overexpression of serotonin or muscarinic receptors causes cell transformation, as does expression of constitutively activated mutant forms of a,-adrenergic receptors or of Gi2, G,, G,,, and G,, a-subunits (58). To date, however, with the exception of GiZ~, mentioned above, mutated forms of these genes have not been identified in naturally occurring human tumors. By analogy with the activated TSH receptor found in thyroid neoplasms, activating ACTH receptor mutations were sought, but not found, in adrenal cortical neoplasms (59). Likewise, in a series cf nine pituitary thyrotroph tumors there was no evidence for activating mutations of the TRH receptor or of G,, G,, or G,, a-subunits (60). Some GPCR, such as somatostatin and D2-dopaminergic receptors, may act as negative growth regulators (e.g. in somatotrophs and lactotrophs, respectively). Somatic loss of function mutations of these GPCR genes or of the G proteins (G, and G,) to which they couple could lead to neoplasia, as would the loss of other tumor-suppressor genes. Such mutations of the D2-dopamine receptor were not identified in a series of prolactinomas (61); nonetheless, further studies of these and other endocrine tumors are warranted.
Further study of GPCR and G proteins is needed in nonneoplastic endocrine disorders as well. Although the clinical consequences of GPCR or G protein mutations are often quite predictable, this is not always the case. Loss of function mutations of the endothelin-B receptor, for example, cause Hirschprung disease through an as yet undisclosed mechanism (62). Transgenic and knock-out mouse approaches should be helpful in elucidating the pathophysiological consequences of such mutations. As discussed previously, some naturally occurring mouse mutants, such as kyt (16) and little (18), mimic human endocrine disorders (TSH and GHRH resistance, respectively). Naturally occurring MSH receptoractivating and -inactivating mutations cause hyper-and hypopigmentation, respectively, in mice (63). The ability to generate artificially mutant mice expands the range of disorders that can be studied in mouse models. Endothelin-B receptor knock-out mice show a phenotype strikingly similar to the human disorder (64). Knock-out of the &-adrenergic receptor in mice helps predict the potential consequences (or lack of consequences) of loss of function mutation of this receptor in humans (65). Knock-out of the mouse Gi,cll gene unexpectedly caused an ulcerative colitis-like disease in null homozygotes (66). This and other surprising phenotypes associated with future knock-out models should prompt studies of signal transduction components in disorders not previously linked to abnormalities in G protein-coupled signal transduction.
Better studies are needed to help elucidate the role, if any, of more subtle abnormalities, including minor quantitative changes and differences in posttranslational modifications such as phosphorylation, in G protein-coupled signal transduction in human disease. The significance of naturally occurring polymorphisms in GPCR and G proteins in particular deserves further study. Certain TSH receptor polymorphisms (aspartate 36 to histidine and proline 52 to threonine) have been claimed to predispose to Graves' disease, but the importance of these differences has been questioned (42). Polymorphisms in the glucagon receptor (glycine 40 to serine) (67) and in the /3,-adrenergic receptor (tryptophan 64 to arginine) (68) have been identified and associated with type II diabetes and a reduced resting metabolic rate, respectively. In neither case, however, has the pathophysiological significance of the altered sequence been conclusively demonstrated.
Finally, it should be clear to the reader that defects in G protein-coupled signal transduction may involve more than defective GPCR or G protein a-subunits. This review has focused on these two components because they have been best studied and harbor most of the known mutations in endocrine disorders (indeed, for defects in G protein a-subunits in human disorders, it is principally G,cu that has been studied; Table 2 ). With the increasing appreciation of the importance of ply-subunits in signal transduction (4), they as well as G protein-regulated effecters and further downstream components will require analysis for possible diseasecausing lesions. The pathophysiological importance of proteins, such as GPCR kinases, involved in agonist-dependent desensitization has already been demonstrated in transgenic mouse models (69), so that studies of these components should be particularly fruitful in disorders characterized by changes in sensitivity to GPCR agonists.
Implications for diagnosis and treatment
The identification of naturally occurring mutations of GPCR and G protein a-subunits as causes of endocrine diseases has already had major implications for understanding the structure and function of these signaling proteins. From an intellectual standpoint, defining critical receptor residues by identification of mutations causing an obvious phenotype such as ND1 is much more efficient than random or saturation mutagenesis. The ability of certain mutations (e.g. residues in transmembrane helix 6 in the LH receptor; alanine 366 to serine in Gscy) to cause constitutive activation provides novel insights into the molecular basis for signal transducwith the development of safer and more efficient gene thertion (36, 49) . The differing clinical consequences of certain apy methods, one can envision somatic gene replacement mutations (e.g. the ability of activating mutations of G,cu to treatment for disorders caused by simple loss of function cause precocious puberty in both females and males, mutations and, possibly, treatment of disorders caused by whereas activating LH receptor mutations trigger precocious activating mutations with appropriate dominant negative puberty only in males) also provide valuable insights into genes. These ideas may seem fanciful at present, but the idea normal physiological regulation. However, what are the imthat disorders such as MAS or FHH are due to point mutaplications of identifying GPCR and G protein mutations for tions in a G protein or GPCR might have seemed equally diagnosis and treatment of endocrine disorders?
fanciful just a few years ago. Unfortunately, as yet, the implications are rather limited, a situation similar to the general status of human genetic disorders despite the impressive recent progress in disease gene identification. For most endocrine disorders, functional diagnosis still depends on measurement of relevant hormone concentrations, and treatment still consists primarily of replacement of the deficient hormone(s) or correction by medical or surgical treatment of hormone hypersecretion. Genetic diagnosis does have immediate practical implications in certain conditions. In X-linked NDI, for example, it is now possible by V2-vasopressin receptor mutation analysis to determine whether a clinically unaffected female is a mutation carrier, and whether her male offspring are at risk for disease. At risk males can be tested immediately postnatally or, in theory, even prenatally to determine if they are affected, and if so, appropriate fluid replacement can be started immediately to avoid any dehydration (22). As most kindreds with X-linked ND1 have distinct mutations, no simple diagnostic test is available, but the V2-vasopressin receptor gene is relatively small (-1.7 kilobases), and mutation analysis of it is straightforward in most molecular genetics labs. Mutation analysis of the CaR gene, which is much larger, is a more formidable task, but may be helpful in distinguishing FHH from primary hyperparathyroidism in hypercalcemic subjects (32). The distinction is not academic, because in FHH, parathyroidectomy is generally not indicated, whereas it generally is in hyperparathyroidism.
As not all kindreds with FHH are linked to the CaR gene on chromosome 3q, and mutations have not always been identified even in kindreds linked to 3q, failure to find a CaR mutation does not exclude FHH (32). Identification of constitutively activated G,(Y in a subset of somatotroph tumors causing acromegaly and in involved tissues from subjects with MAS may be important in predicting responsiveness to treatment with somatostatin. In uitvo studies of somatotroph tumors showed that those harboring G,a mutations were much more likely to respond with a reduction in GH secretion than those lacking such mutations (70). Somatostatin has been effective in uizm in reducing GH hypersecretion in subjects with MAS (71). This suggests that although CAMP formation by adenylyl cyclase is being stimulated by constitutively activated Gs~, it is still susceptible to inhibition by input from Gi proteins activated by somatostatin receptors. This also suggests that other agents capable of reducing CAMP formation could be effective in treating disorders caused by constitutive G,a-or G,-coupled receptor activation. Jn vim studies in transgenic mice have shown that inverse agonists can block constitutive p-adrenergic receptor activation (6). It is possible that inverse agonists could be developed specifically for other receptors whose constitutive activation causes disease. Eventually, 
